GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating six solid tumor types, including prostate, breast, head and neck, ovarian, lung, and GIGTB-7550 TriKE® is in preclinical development for autoimmune indications and targets CD19Cash of approximately $9.2 million as of June 30, 2024, anticipated to be sufficient to fund operations into 2025 SAN FRANCISCO, CALIFORNIA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical